Regeneron’s Q2 2026 earnings call drew CEO Leonard Schleifer, CSO George Yancopoulos, Commercial EVP Marion McCourt, and CFO Christopher Fenimore.
Revenue rose 17% to USD 4.3 billion; non-GAAP EPS increased 11% to USD 14.29, including a USD 0.99 hit from acquired IPR&D charges.
EYLEA HD U.S. net sales reached USD 596 million, up 52%; management targeted EYLEA HD prefilled-syringe clearance before year-end using more than two CMOs.
Sanofi collaboration revenue hit USD 2.2 billion; Fenimore flagged a step-up starting Q3 as the USD 3.1 billion Sanofi development balance was fully repaid.
Management guided to an August FDA action for garetosmab in FOP; a November FDA decision for cemdisiran in gMG; and a PNH registrational readout in Q4.
REGN•
